NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society...

NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm
Society Conference

Data demonstrates that NewCardio's platform technology delivers new levels of
analysis of heart's electrical activity

SANTA CLARA, Calif., May 18 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC
Bulletin Board: NWCI) a cardiac diagnostic and services company, today
announced that members of the Company's medical and technology teams presented
two abstracts and discussed new clinical data from analytical and clinical
applications of its proprietary platform technology at The Heart Rhythm
Society (HRS) 30th Annual Scientific Sessions on May 13-16, 2009 in Boston,
MA.

NewCardio introduced the NewCardio platform, QTinno(TM) and Visual3Dx(TM), at
Heart Rhythm 2009 30th Annual Scientific Sessions. The Company believes that
its QTinno(TM), software-based, analytical technology is the industry's first
solution for the reliable automated analysis of ECGs used to determine cardiac
toxicity during drug development. Visual3Dx(TM) will generate 3D information
from the heart using standard 12-lead ECG data. It is expected to provide
clinicians additional information on the extent and localization of acute
ischemic insult to the heart to improve the speed and accuracy of diagnosis of
Acute Coronary Syndrome.

HRS is the international leader in science, education and advocacy for cardiac
arrhythmia professionals and patients, and the primary information resource on
heart rhythm disorders. Its mission is to improve the care of patients by
promoting research, education and optimal health care policies and standards.
The Annual Scientific Sessions attract more than 9,000 professionals
representing the allied specialties of cardiac pacing and cardiac
electrophysiology. More information is available at
http://www.hrsonline.org/Sessions/ on the Internet.

The two abstracts presented were:

"Vectorcardiographic Evidence of Cardiac Memory During Continuous Ventricular
Pacing," authored by Drs. Alexei Shvilkin, Mark Josephson and Peter Zimetbaum,
all of the Department of Medicine/Division of Cardiology at the Beth Israel
Deaconess Medical Center/Harvard Medical School in Boston, as well as Drs.
Bosko Bojovic (NewCardio's co-founder and senior consultant), Branislav Vajdic
(NewCardio's Chief Executive Officer), and Ihor Gussak (NewCardio's Chief
Medical Officer). This study presents data demonstrating the ability to
identify cardiac memory (post-pacing T wave abnormality) during continuous
ventricular pacing using the Company's 3-dimensional ECG interpretation tools.
Previously, this phenomenon was only described in the setting of a return to
normal ventricular activation. This observation advances our understanding of
wide complex rhythms physiology and serves as a basis for improving ECG
diagnosis in the setting of abnormal ventricular activation (left bundle
branch block (LBBB) and ventricular pacing).

"Vectorcardiographic Discrimination Between Acute and Chronic Left Bundle
Branch Block," authored by Drs. Shvilkin, Josephson and Zimetbaum from the
Beth Israel Deaconess Medical Center/Harvard Medical School, as well as Drs.
Bojovic, Vajdic and Gussak. The study demonstrates that by using NewCardio's
platform technology, it is possible to distinguish new onset left bundle
branch block (LBBB) from a chronic one. This constitutes a significant
diagnostic advance in a setting of acute coronary syndrome (ACS). Currently,
new or presumed new onset LBBB is a Class I indication for primary
percutaneous coronary intervention or fibrinolytic therapy in patients
presenting with symptoms consistent with ACS. Up until now there have been no
diagnostic criteria to distinguish new onset from chronic LBBB and if no prior
ECGs were available it had to be presumed "new." NewCardio technology allows
the reader to determine the duration of LBBB without previous ECG tracings.
This finding can potentially reduce the number of unnecessary coronary
interventions.

Branislav Vajdic, PhD, NewCardio's Chief Executive Officer, commented, "These
two abstracts clearly demonstrate the power of NewCardio's platform technology
in difficult clinical settings. This solution enables doctors to obtain much
more clinically relevant information than previous technologies allowed,
setting the stage for clinical advances which have the potential to save lives
by more rapidly and accurately diagnosing cardiac events. We are excited to
have had the opportunity to discuss these findings at the Heart Rhythm Society
conference, the premier gathering for the electrophysiology community."

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the
development of a proprietary platform technology to provide higher accuracy
to, and increase the value of, the standard 12-lead electrocardiogram (ECG).
NewCardio's development-stage software and hardware products and services are
intended to improve the diagnosis and monitoring of cardiovascular disease
(CVD), as well as cardiac safety assessment of drugs under development.
NewCardio's three-dimensional ECG platform is designed to reduce the time and
expense involved in assessing cardiac status while increasing the ability to
diagnose clinically significant conditions which were previously difficult to
detect. For more information, visit www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements include, but are not limited to, statements that express our
intentions, beliefs, expectations, strategies, predictions or any other
statements relating to our future activities or other future events or
conditions. These statements are based on current expectations, estimates and
projections about our business based on currently available information and
assumptions made by management. Although we believe that the assumptions on
which the forward-looking statements contained herein are based are
reasonable, any of those assumptions could prove to be inaccurate given the
inherent uncertainties as to the occurrence or nonoccurrence of future events.
These statements are not guarantees of future performance and involve risks
and uncertainties that are difficult to predict. Therefore, actual outcomes
and results may, and are likely to, differ materially from what is expressed
or forecasted in the forward-looking statements due to numerous factors,
including the potential risks and uncertainties set forth in Item 1A of our
Annual Report on Form 10-K for the year ended December 31, 2008 and relate to
our business plan, our business strategy, development of our proprietary
technology platform and our products, timing of such development, timing and
results of clinical trials, level and timing of FDA regulatory clearance or
review, market acceptance of our products, protection of our intellectual
property, implementation of our strategic, operating and people initiatives,
benefits to be derived from personnel and directors, ability to commercialize
our products, our assumptions regarding cash flow from operations and cash
on-hand, the amount and timing of operating costs and capital expenditures
relating to the expansion of our business, operations and infrastructure,
implementation of marketing programs, our key agreements and strategic
alliances, our ability to obtain additional capital as, and when, needed, and
on acceptable terms and general economic conditions specific to our industry,
any of which could impact sales, costs and expenses and/or planned strategies
and timing. We assume no obligation to, and do not currently intend to, update
these forward-looking statements.

To join our email distribution please click this link:
http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

Investor Contact:
Hayden IR
Jeff Stanlis
Partner and Vice President of Communications
(602) 476-1821
jeff@haydenir.com

SOURCE NewCardio, Inc.

Jeff Stanlis, Partner and Vice President of Communications of Hayden IR,
+1-602-476-1821, jeff@hayednir.com, for NewCardio, Inc.